Evaluation of Omeprazole Effect on Glaucoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2009 by Shahid Beheshti Medical University.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Ophthalmic Research Center
Information provided by:
Shahid Beheshti Medical University
ClinicalTrials.gov Identifier:
NCT01000220
First received: July 7, 2009
Last updated: May 3, 2010
Last verified: October 2009
  Purpose

Omeprazole is a safe drug listed in OTC drug due to its safety. It acts by irreversible inhibition of K/H ATP ase pump and also Na/K ATP ase, Na/H ATP ase.Considering these actions the effect of omeprazole on decreasing intra ocular pressure is an issue of debate.In this Randomized Clinical Trial conducted in labafinejad hospital, patients with glaucoma who need to take omeprazole due to GI problem are evaluated in two groups including placebo and drug users. The effect will be finally assessed.


Condition Intervention Phase
Glaucoma
Drug: Omeprazole
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Evaluation of Omeprazole Effect on Glaucoma

Resource links provided by NLM:


Further study details as provided by Shahid Beheshti Medical University:

Arms Assigned Interventions
Active Comparator: Omeprazole Drug: Omeprazole
Placebo Comparator: placebo Drug: Placebo

Detailed Description:

Omeprazole is a safe drug listed in OTC drug due to its safety. It acts by irreversible inhibition of K/H ATP ase pump and also Na/K ATP ase, Na/H ATP ase.Considering these actions the effect of omeprazole on decreasing intra ocular pressure is an issue of debate.In this Randomized Clinical Trial conducted in labafinejad hospital, patients with glaucoma who need to take omeprazole due to GI problem are evaluated in two groups including placebo and drug users. The effect will be finally assessed.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients with glaucoma
  • 18 to 70 years
  • POAG patients, Pseudoexfoliation
  • no history of other systemic disease
  • no history of intraocular intervention
  • no history of H2 blocker or PPI consumption during the past month consuming 2 or less topical anti-glaucoma medication
  • no present immune deficiency
  • no addiction habit

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01000220

Contacts
Contact: Yazdani Shahin, MD +982122585952 labbafi@hotmail.com

Locations
Iran, Islamic Republic of
Ophthalmic Research Center Recruiting
Tehran, Iran, Islamic Republic of, 166666
Contact: Shahin yazdani, MD    +98 21 22585952    labbafi@hotmail.com   
Sponsors and Collaborators
Shahid Beheshti Medical University
Ophthalmic Research Center
  More Information

No publications provided

Responsible Party: Ophthalmic Research Center
ClinicalTrials.gov Identifier: NCT01000220     History of Changes
Other Study ID Numbers: 8735
Study First Received: July 7, 2009
Last Updated: May 3, 2010
Health Authority: Iran: Ethics Committee

Additional relevant MeSH terms:
Glaucoma
Ocular Hypertension
Eye Diseases
Omeprazole
Anti-Ulcer Agents
Gastrointestinal Agents
Therapeutic Uses
Pharmacologic Actions
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 01, 2014